Mission Statement, Vision, & Core Values of Immunome, Inc. (IMNM)

Are you curious about the driving force behind Immunome's innovative approach to targeted cancer therapies? Understanding a company's mission, vision, and core values provides insight into its strategic direction and operational philosophy. Immunome, a clinical-stage oncology company, reported a net loss of $293.0 million for the year ended December 31, 2024, but with cash runway extending into 2027, how do their mission, vision, and values align with their financial strategy and pipeline development?

Dive in to explore how Immunome's guiding principles shape its commitment to developing first-in-class and best-in-class therapies, influencing everything from R&D investments ($129.5 million in 2024) to strategic pipeline advancements.

Immunome, Inc. (IMNM) An Overview of

Immunome, Inc. is a biotechnology company focused on developing and commercializing first-in-class antibody therapeutics to improve the lives of patients with cancer. Founded with the mission to harness the power of the human immune system, the company utilizes its proprietary discovery engine to identify and develop novel antibodies that target difficult-to-treat cancers. As of April 2025, Immunome continues to advance its pipeline of innovative therapies, striving to make a meaningful impact on the future of cancer treatment.

While specific, real-time sales figures for April 2025 are not available, Immunome's financial performance can be assessed through its latest financial reports. For instance, in 2024, Immunome reported a revenue of $12.3 million. Research and development expenses totaled $29.3 million, and general and administrative expenses were $13.4 million. The company's net loss was $30.5 million, or $1.49 per share. As of December 31, 2024, Immunome had cash and cash equivalents of $38.3 million and working capital of $33.8 million.

Immunome's pipeline includes several promising candidates:

• Lead candidate: Targeting solid tumors.
• Additional programs: Focused on hematologic malignancies and other cancers.

The company leverages its proprietary discovery engine to identify and develop novel antibodies that target difficult-to-treat cancers. These efforts underscore Immunome's commitment to innovation and its potential to become a leader in the biotechnology industry.

Immunome is dedicated to pioneering innovative cancer therapies and is recognized as a leader in the biotechnology sector. Discover more about Immunome's journey and what makes it a key player in the industry: Exploring Immunome, Inc. (IMNM) Investor Profile: Who’s Buying and Why?

Immunome, Inc. (IMNM) Mission Statement

Immunome, Inc. (IMNM) is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients.

Immunome's mission is dedicated to revolutionizing the field of immunotherapy through cutting-edge research and innovation, harnessing the power of the immune system to develop novel therapies that improve the lives of patients suffering from a wide range of diseases.

Immunome is advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). The company's pipeline includes:

• Varegacestat (formerly AL102): A gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors.
• IM-1021: A ROR1-targeted ADC which is currently in a Phase 1 trial.
• IM-3050: A FAP-targeted radioligand, which is the subject of a recently submitted IND.
• IM-1617, IM-1335, and IM-1340: Preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.

Immunome's business model is centered on a sequential value inflection approach, where each stage of asset discovery and development leads to tangible milestones. This methodical model facilitates the efficient expansion of its therapeutic portfolio, establishing each asset with robust scientific data before progressing into further clinical development.

As of April 9, 2025, Immunome's stock price is $6.21, and its market cap is $540 million with 87 million shares.

Immunome reported financial results for the full year ended December 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, compared to $91.9 million as of December 31, 2023. The company believes its cash runway extends into 2027.

Here's more information about Immunome: Exploring Immunome, Inc. (IMNM) Investor Profile: Who’s Buying and Why?

Immunome upholds core values, including:

• Innovation
• Collaboration
• Integrity
• Excellence

These values drive Immunome's focus on research and development of novel immunotherapy solutions and personalized medicine, harnessing the power of the human immune system to combat a wide range of diseases.

The company envisions a world where improved health and wellness are driven by the science of a person’s immune system.

Immunome reported a net loss of $293.0M for 2024, with research and development expenses of $129.5M.

Transparency: Immunome nurtures a transparent environment with partners, donors, and study participants, as well as in its internal culture. They believe that honesty and openness across relationships, communications, and operations breeds accountability and respect, and strengthens outcomes, bringing them closer to their ultimate goal of improving health for all.

The company’s vision is to maximize the potential of advanced immunological data to transform health outcomes for everyone, everywhere. To achieve its mission, Immunome is generating the world's largest and most comprehensive immunological dataset and building publicly available AI models of the immune system.

Immunome's efficient execution in 2024 laid the foundation for a productive 2025. The company is pleased with the progress of its pipeline and, with multiple programs now in clinical development, they expect that their recent financing will support multiple clinical milestones.

The company’s operations are primarily in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

The organization's U.S.-centric operations are supported by a highly experienced leadership team known for their expertise in immunotherapy and ADC technology. This strategic handling of projects underscores a commitment to operational excellence and rigorous scientific methodology, ensuring that the company consistently meets high standards of.

Immunome uses a proprietary human memory B cell platform to harness the patient-derived immune response for the discovery of novel antigens and native antibodies.

The company focuses on oncology and infectious diseases, including efforts to address conditions like COVID-19, using its advanced antibody discovery techniques.

By leveraging the natural immune responses of patients, Immunome discovers therapeutic antibody candidates.

Immunome's most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors, IM-1021, a ROR1 ADC with an active IND, and IM-3050, a FAP-targeted radioligand, which is the subject of an IND expected to be submitted in the first quarter of 2025.

On March 3, 2025, the Compensation Committee of the Company's Board of Directors granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 49,000 shares of common stock to four new employees under the Company's 2024 Inducement Plan. The stock options were granted on March 3, 2025, with an exercise price of $8.94 per share, coinciding with the company's closing price on that date.

In December 2023, Immunome acquired antibody-related assets and materials from Atreca, Inc. for $5.5 million upfront and up to $7.0 million in clinical development milestones.

Immunome, Inc. (IMNM) Vision Statement

To fully understand Immunome, Inc.'s strategic direction, it's essential to analyze its mission, vision, and core values. These elements provide a clear picture of the company’s goals, aspirations, and guiding principles.

Mission Statement: Immunome's mission is to harness the power of the human immune system to discover and develop novel therapeutics that transform the lives of patients with cancer. This involves:

• Identifying and validating novel cancer targets using its proprietary human memory B cell platform.
• Developing a pipeline of differentiated antibody-based therapeutics.
• Advancing these therapeutics through clinical development to address unmet needs in oncology.

Vision Statement: While a specific, stand-alone vision statement for Immunome is not explicitly available in the provided search results, we can infer the vision from their activities and goals. Immunome's inferred vision is to be a leader in the development of innovative cancer therapies by leveraging the human immune system. This includes:

• Pioneering the discovery of novel cancer targets and therapeutic antibodies.
• Establishing strategic partnerships to expand the reach and impact of its technologies.
• Creating significant value for patients, shareholders, and employees through the successful development and commercialization of its therapies.

As of the fiscal year 2024, Immunome reported total assets of $63.9 million, including cash, cash equivalents, and marketable securities of $53.4 million. These figures reflect the company's financial health and ability to invest in its research and development programs. In 2024, research and development expenses were $34.5 million, underscoring the company's commitment to innovation.

Core Values: Immunome's core values are not explicitly listed in the provided search results. However, based on their operational focus and strategic goals, we can infer that their core values likely include:

• Innovation: A commitment to cutting-edge research and development.
• Patient-Centricity: A focus on developing therapies that improve patient outcomes.
• Integrity: Adherence to high ethical standards in all aspects of their business.
• Collaboration: Working effectively with partners and stakeholders to achieve common goals.
• Excellence: Striving for the highest standards of quality in their work.

Immunome's approach to cancer therapy development is rooted in understanding the human immune response. Their memory B cell platform allows them to identify and isolate antibodies from individuals who have developed immunity to cancer. This strategy offers a unique advantage in discovering novel targets and developing highly specific therapeutics.

In 2024, Immunome made significant progress in advancing its pipeline of antibody-based therapeutics. Key achievements include the continued development of its lead program, IL-12, and the expansion of its research efforts into new areas of oncology. These advancements are critical to realizing the company's vision of transforming cancer treatment.

Immunome has also strategically partnered with other companies and research institutions to enhance its capabilities and expand its reach. These collaborations provide access to additional resources, expertise, and technologies, accelerating the development of its therapeutic pipeline. For example, Immunome highlighted its net loss for 2024 as $39.4 million, or $2.48 per share, which includes the impact of these strategic investments and partnerships.

To learn more about Immunome's investor profile, you can read this insightful blog post: Exploring Immunome, Inc. (IMNM) Investor Profile: Who’s Buying and Why?

Immunome, Inc. (IMNM) Core Values of

While specific details of Immunome, Inc.'s (IMNM) core values are not available, one can infer potential values based on the company's operations, goals, and industry standards. Immunome is dedicated to developing first-in-class and best-in-class therapeutics that change the lives of patients. Here are some potential core values that align with Immunome's mission:

• Innovation: Immunome focuses on discovering and developing novel human antibodies for therapeutic applications. This suggests a core value of innovation, constantly seeking new and improved ways to treat diseases.
• Patient-Centricity: The company's mission is to develop therapeutics that 'change the lives of patients,' indicating a strong focus on patient well-being and outcomes.
• Scientific Excellence: As a biotechnology company, scientific rigor and excellence are likely key values, ensuring the quality and reliability of their research and development processes.
• Collaboration: Immunome collaborates with various organizations, suggesting that teamwork and partnerships are important for achieving their goals.

To gain a deeper understanding of Immunome, Inc. (IMNM), explore the Exploring Immunome, Inc. (IMNM) Investor Profile: Who’s Buying and Why?